Journal
VACCINES
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/vaccines10040491
Keywords
SARS-CoV-2; COVID-19; heterologous vaccination; anti-S antibodies; IgG anti-S response
Categories
Funding
- Fondo sanzioni SPSAL (Servizio di Prevenzione e Sicurezza Ambienti di Lavoro) [0210399]
- Fondi d'Ateneo Covid-Lab
Ask authors/readers for more resources
This study evaluated the post-vaccination humoral response in three real-world cohorts and found that a heterologous vaccine schedule induced a significantly higher humoral response. The type of vaccine was the main factor influencing antibody titer, and the study showed that using a heterologous vaccination strategy was safe with minimal side effects.
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination from a total of 1248 subjects. The results showed that the heterologous vaccine schedule induced a significantly higher humoral response followed by homologous BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S vaccines (p < 0.0001). Moreover, analyzing factors (i.e., vaccine schedule, sex, age, BMI, smoking, diabetes, cardiovascular diseases, respiratory tract diseases, COVID-19 diagnosis, vaccine side effects) influencing the IgG anti-S response, we found that only the type of vaccine affected the antibody titer (p < 0.0001). Only mild vaccine reactions resolved within few days (40% of subjects) and no severe side effects for either homologous groups or the heterologous group were reported. Our data support the use of heterologous vaccination as an effective and safe alternative to increase humoral immunity against COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available